Solosa

Glimepiride

NIDDM, whenever blood glucose levels cannot be controlled adequately by diet, physical exercise & wt reduction alone.

Initially 1 mg once daily. Dose can be increased gradually, guided by regular blood glucose monitoring w/ an interval of 1-2 wk according to the following dose steps: 1 mg-2 mg-3 mg-4 mg-6 mg (-8 mg). Patient w/ well-controlled diabetes 1-4 mg daily.

Should be taken with food: Take immediately before the 1st main meal of the day. Do not skip meals. Swallow whole w/ some liqd (approx ½), do not chew.

Hypersensitivity to glimepiride, other sulfonylureas or sulfonamides. Insulin dependent (type 1) DM eg, diabetics w/ a history of ketoacidosis, diabetic ketoacidosis or diabetic precoma or coma. Pregnancy & lactation.

Exceptional stress situations eg, trauma, surgery, febrile infections. Increased risk of hypoglycemia in patients unwilling or incapable to cooperate during treatment; undernourishment, irregular mealtimes or skipped meals; imbalance between physical exertion & carbohydrate intake; alterations of diet; consumption of alcohol especially in combination w/ skipped meals; severe liver impairment; overdosage w/ glimepiride; uncompensated endocrine system disorders affecting carbohydrate metabolism eg, certain thyroid function disorders, anterior pituitary or corticoadrenal insufficiency; concurrent treatment w/ other certain medications; treatment w/ glimepiride w/o any indications. Severe hypoglycemia. Patients w/ G6PD-deficiency. May impair ability to drive & use machines. Elderly.

Hypoglycemia & other additional signs of adrenergic counter-regulation eg, sweating, clammy skin, anxiety, tachycardia, HTN, palpitations, angina pectoris & cardiac arrhythmias; temporary visual impairment; nausea, vomiting, sensations of pressure or fullness in the epigastrium, abdominal pain, diarrhea, dysgeusia; allergic or pseudoallergic reactions eg, itching, urticaria or rashes, dyspnoea & fall in BP, sometimes progressing to shock. Alopecia, wt gain. Decrease in serum Na conc & allergic vasculitis or hypersensitivity of the skin to light.

Potentiated effect w/ insulin & other oral antidiabetics, ACE inhibitors, anabolic steroids & male sex hormones; chloramphenicol, coumarin derivatives, cyclophosphamide. disopyramide, fenfluramine, fenyramidol, fibrates, fluoxetine, guanethidine, ifosfamide, MAOIs, miconazole, fluconazole, para-amino salicylic acid, pentoxifylline, phenylbutazone, azapropazone, oxyphenbutazone, probenecid, quinolones, salicylates, sulfinpyrazone, clarithromycin, sulfonamide antibiotics, tetracyclines, tritoqualine, trofosfamide. Weakened blood-glucose lowering effect w/ acetazolamide, barbiturates, corticosteroids, diazoxide, diuretics, epinephrine & other sympathomimetics, glucagon, laxatives, nicotinic acid, estrogens & progestogens, phenothiazines, phenytoin, rifampicin, thyroid hormones. May lead to either potentiation or weakening of effect w/ H₂ receptor antagonists, β-blockers, clonidine & reserpine, acute & chronic alcohol intake. Potentiated or weakened effect of coumarin derivatives. Bile acid sequestrant.

Antidiabetic Agents

A10BB12 - glimepiride ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.

Rx